# Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

> **NCT00377585** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3350 (—)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluarix
- **BIOLOGICAL:** adjuvanted influenza vaccine

## Key facts

- **NCT ID:** NCT00377585
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-22
- **Primary completion:** —
- **Final completion:** 2007-01-30
- **Target enrollment:** 3350 (—)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377585, "Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00377585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*